Premium
Interleukin‐17 inhibitor, is it safer than tumor necrosis factor inhibitor?
Author(s) -
Huang Jinxian,
Zhang Lijun,
Wei James CC
Publication year - 2021
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.14076
Subject(s) - medicine , psoriatic arthritis , tnf inhibitor , ankylosing spondylitis , arthritis , population , antirheumatic drugs , drug , clinical trial , tumor necrosis factor alpha , etanercept , intensive care medicine , immunology , antirheumatic agents , pharmacology , environmental health